Dr. Luis Jodar is Chief Medical Officer for Vaccines Medical Development and Medical/Scientific Affairs at Pfizer Inc. In this capacity, Dr. Jodar heads Pfizer’s vaccines medical development, clinical and scientific affairs worldwide comprising around 200 MD, PhD vaccinologists. Dr. Jodar has held different positions at Pfizer including Vice President, Global Vaccines, Medicines Development Group and Scientific Affairs; Head of Vaccines, Medical Affairs for Emerging Markets and Executive Director for Clinical and Scientific Affairs for the Asia Pacific (AP) region at Wyeth.
Before joining industry, Dr. Jodar was Deputy Director General at the International Vaccine Institute (IVI) in Seoul, Korea, an international organization established by the United Nations for the development, introduction and use of new vaccines and adjunct professor at Seoul National University, Faculty of Medicine, School of Public Health. At the IVI, he was responsible of directing the IVI’s Translational Research Division which conducts programs of interdisciplinary research, including pre-licensure and post-licensure clinical trials, epidemiological research, studies of the economics of vaccine introduction, sociobehavioral and policy research on vaccines against cholera, typhoid fever, shigellosis, rotavirus, Japanese encephalitis, Haemophilus influenzae b, and Streptococcus pneumoniae.
Previously, Dr. Jodar worked at the World Health Organization (WHO) leading the global vaccine research and introduction of meningococcal vaccines, activities related to adverse events allegations and quality, safety and correlates of protection of vaccines. Previously he was the focal point of the Task Force for Vaccines and Viral Diseases at the European Commission in Brussels.
Dr. Jodar is a neuroimmunologist with doctoral and post-doctoral training in Madrid, Osaka and Nagasaki Universities. Dr. Jodar has worked in vaccine-related programs in more than 50 countries around the world including developing countries in Africa, Asia and Latin America, published in the most accredited peer-review journals (e.g. the Lancet, New England Journal of Medicine, Nature Medicine), and served on a number of advisory groups on vaccines to WHO, the EU, vaccine manufacturers and governments. He teaches at the Institut Pasteur, ADVAC and Columbia University and has a long track-record in launching and coordinating public private vaccine development partnerships to accelerate the development, clinical evaluation, registration, introduction and commercialization of vaccines of public health importance for developing and middle-income countries having received more than $100M in grants. He has also been awarded with several honors including the “cross of officer of the order of civil merit” from the King of Spain for his work in vaccines and vaccination in developing countries.
Org chart
Teams
Offices
This person is not in any offices
Pfizer
577 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.
